Mutated Soluble Alkaline Phosphatase for Less Frequent HPP Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for hypophosphatasia, such as asfotase alfa, face challenges with compliance due to frequent injections and injection site reactions, necessitating improvements in dosing frequency and volume to enhance patient quality of life.
Innovation Solution
Development of recombinant alkaline phosphatases with specific mutations that improve catalytic activity, stability, and pharmacokinetic properties, potentially combined with a bone-targeting moiety and an Fc region, to enhance therapeutic efficacy and reduce dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If asfotase alfa is administered three to six times weekly via subcutaneous injection, then therapeutic benefits are achieved, but compliance becomes challenging and injection site reactions occur
Solution Approach 1:
The patent applies parameter changes by modifying the dosing frequency from three to six times weekly to once monthly, and changing the administration route from subcutaneous to intravenous. This fundamentally alters the treatment parameters to improve compliance while maintaining therapeutic efficacy through the engineered alkaline phosphatase variants with enhanced properties.
Solution Approach 2:
The patent employs dynamics by creating engineered alkaline phosphatase variants with modified properties that adapt to different physiological conditions. The enzyme variants are designed with enhanced stability and activity characteristics that allow for less frequent dosing, making the treatment regimen more flexible and manageable for patients.
2Reliability
If asfotase alfa is administered via subcutaneous injection, then enzyme replacement therapy is delivered, but injection site reactions occur
Solution Approach 1:
The patent applies the extraction principle by removing the enzyme from the subcutaneous injection route and transitioning to intravenous administration. This extracts the therapeutic agent from the problematic delivery method that causes injection site reactions, while maintaining the essential function of enzyme replacement therapy through the engineered alkaline phosphatase variants.
3Ease of operation
If dosing frequency is reduced to improve compliance, then quality of life improves, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent resolves this contradiction through parameter changes by engineering alkaline phosphatase variants with enhanced catalytic activity, stability, and half-life properties. These modified enzyme parameters allow for extended dosing intervals (once monthly) while maintaining sufficient therapeutic efficacy, thus improving compliance without compromising treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated alkaline phosphatases demonstrate enhanced catalytic activity, temperature stability, and substrate specificity, allowing for less frequent dosing and improved bone mineralization, muscle strength, and motor function in patients with hypophosphatasia.
Implementation Method 1
The mutated alkaline phosphatases demonstrate enhanced catalytic activity
Implementation Method 2
The mutated alkaline phosphatases demonstrate enhanced catalytic activity, temperature stability
Data Source
AI summary
Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).